News
SEEL
0.6150
-3.80%
-0.0243
Weekly Report: what happened at SEEL last week (0318-0322)?
Weekly Report · 3d ago
SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023
Seelos Therapeutics reported earnings per share of -79 cents for the fourth quarter of 2023. The company reported revenue of $653,000. This was above the analyst estimate for EPS of -80 cents. Seelos is a biopharmaceutical company.
Investorplace · 5d ago
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. Dipped 31.7% to $4.91 on Wednesday. ETAO International Co., Ltd. Shares shot up 111.5% after the company announced a reverse stock split. NuScale Power Corporation shares tumbled around 35% after spiking 17% on Tuesday.
Benzinga · 03/20 18:03
12 Health Care Stocks Moving In Wednesday's Intraday Session
XTL Biopharmaceuticals shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. Etao International Co (NASDAQ:ETAO) stock rose 84.65% in the session. Annovis Bio (NYSE:ANVS) shares moved up by 39.12%. The company's Q4 earnings report came out yesterday.
Benzinga · 03/20 17:31
Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results
TipRanks · 03/20 09:56
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
U.S. Stocks traded higher toward the end of trading on Tuesday. The Dow traded up 0.63% and the Nasdaq Composite gained more than 50 points. Energy shares rose by 1% after Caleres Inc. Reported upbeat fourth-quarter results. European markets closed mostly lower in Asia Pacific markets.
Benzinga · 03/19 19:02
BUZZ-U.S. STOCKS ON THE MOVE-US energy sector, Avis, NuScale
The tech-laden Nasdaq dipped on Tuesday with chip stocks falling to more than two-week lows. The Dow Jones Industrial Average was up 0.67% as focus turned to the Federal Reserve's policy meeting. The top three S&P 500 percentage gainers were International Paper Co, up 10%.
Reuters · 03/19 17:48
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. Fell sharply after the company reported worse-than-expected fourth-quarter EPS results. Ontrak, Inc. Shares climbed 197.8% to $0.5660 in Tuesday's mid-day session. Fusion Pharmaceuticals Inc. Gained 97.3% after agreeing to be acquired by AstraZeneca.
Benzinga · 03/19 17:48
12 Health Care Stocks Moving In Tuesday's Intraday Session
Ontrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. Fusion Pharmaceuticals stock moved upwards by 97%. SCWorx stock rose 70.74% and Enliven Therapeutics stock increased by 29.19%. Acutus Medical stock declined by 26.5% during the session.
Benzinga · 03/19 17:31
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
U.S. Stocks traded mixed on Tuesday, with the Dow Jones gaining more than 200 points. Core & Main, Inc. Shares rose 7% after the company reported fourth-quarter results. Energy shares rose by 0.7% on Tuesday; communication services shares fell by 1%. Asian markets closed mostly lower while European shares were mostly higher.
Benzinga · 03/19 16:54
BUZZ-U.S. STOCKS ON THE MOVE-National Cinemedia, Crinetics Pharma, Nordstrom
The S&P 500 and the Nasdaq fell on Tuesday with most megacap and chip stocks weakening. The Dow Jones Industrial Average was up 0.56%. National Cinemedia, Crinetics Pharma, Nordstrom were up. The top three Nasdaq percentage gainers were International Paper, Boeing and Boeing.
Reuters · 03/19 16:05
BUZZ-Seelos falls on failed ALS drug study
Shares of Seelos Therapeutics down 51% at 45 cents. Co's experimental drug for amyotrophic lateral sclerosis failed to meet main goal in a mid-stage trial. Drug SLS-005 did not show any statistical significance in improving function and mortality.
Reuters · 03/19 13:49
Nasdaq Down 100 Points; US Housing Starts Surge In February
U.S. Stocks traded mixed on Tuesday, with the Nasdaq Composite falling around 100 points. The Dow traded up 0.11% and the NASDAQ fell 0.63% on Tuesday. Energy shares rose by 0.4% while information technology shares fell by 1%. Housing starts in the U.s. Surged 10.7% month-over-month to an annualized rate of 1.521 million.
Benzinga · 03/19 13:40
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Seelos Therapeutics provides update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. The company says SLS-005 showed a 13% improvement in Function and Mortality. The study did not meet statistical significance but showed a potential signal of efficacy in a pre-specified subgroup.
Benzinga · 03/19 13:38
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
Seelos Therapeutics shares were down 47% to 48 cents in premarket trading. A Phase 2/3 trial for SLS-005 for amyotrophic lateral sclerosis failed to meet its primary endpoints. The study did show a potential signal of efficacy in a pre-specified subgroup.
Dow Jones · 03/19 13:21
Seelos falls as lead drug fails in ALS trial
Seelos Therapeutics, Inc. Lost 43% premarket on Tuesday after lead drug fails in ALS trial. SLS-005 failed to reach the main goals in a Phase 2/3 trial for patients with amyotrophic lateral sclerosis. The company says there is evidence of efficacy for the drug.
Seeking Alpha · 03/19 13:09
Seelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpoints
NASDAQ · 03/19 13:08
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. Fusion Pharmaceuticals and Enveric Biosciences moved upwards by 97.46% and 39.09% respectively. Losers include Seelos Therapeutics and Acurx Pharmaceuticals.
Benzinga · 03/19 13:05
UPDATE 1-Seelos Therapeutics' ALS treatment fails in mid-stage study
Seelos Therapeutics' shares plunged 51% to 44 cents in trading before the bell. The drug, SLS-005, failed to meet the main goal in a mid-stage trial. ALS is a rare disease that affects the brain and spinal cord.
Reuters · 03/19 12:43
Seelos says ALS treatment fails in mid-stage study
Reuters · 03/19 12:23
More
Webull provides a variety of real-time SEEL stock news. You can receive the latest news about Seelos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.